Objective： To review the prevalence and prognostic significance of fibroblast growth factor receptor 1 （FGFRI） amplification and to establish an association between FGFRI amplification and the clinical characterist...Objective： To review the prevalence and prognostic significance of fibroblast growth factor receptor 1 （FGFRI） amplification and to establish an association between FGFRI amplification and the clinical characteristics of nonsmall cell lung cancer （NSCLC）. Data Sources： We searched PubMed for English-language studies published between January 2010 and May 2016. Study Selection： We included all relevant articles, with no limitation of study design. Results： FGFRI amplification was reported in 8.7-20.0% of NSCLC cases and was significantly more frequent in squamous cell carcinomas （SCCs） （9.7-28.3%） than in adenocarcinomas （ADCs） （0-15.0%）. The rates of FGFRI amplification were as follows： males, 13.9-22.1%; females, 0-20.1%; Stage 1 NSCLC, 9.3-24.1%; Stage II NSCLC, 12.9-25.0%; Stage 111 NSCLC, 8.2-19.5%： Stage IV NSCLC, 0-12.5%; current smokers, 13.3-29.0%; former smokers, 2.5-23.0%; and nonsmokers, 0-22.2%. Overall survival was 43.9-70.8 months in patients with FGFRI amplification and 42.4-115.0 months in patients with no FGFRI amplification; disease-free survival was 22.5-58.5 months and 52.4-94.6 months, respectively. Conclusions： FGFR1 amplification is more frequent in SCCs than in ADCs. The association between FGFRI amplification and clinical characteristics （gender, smoking status, and disease stage） and the prognostic significance of FGFRI amplification in NSCLC remain controversial.展开更多
文摘Objective： To review the prevalence and prognostic significance of fibroblast growth factor receptor 1 （FGFRI） amplification and to establish an association between FGFRI amplification and the clinical characteristics of nonsmall cell lung cancer （NSCLC）. Data Sources： We searched PubMed for English-language studies published between January 2010 and May 2016. Study Selection： We included all relevant articles, with no limitation of study design. Results： FGFRI amplification was reported in 8.7-20.0% of NSCLC cases and was significantly more frequent in squamous cell carcinomas （SCCs） （9.7-28.3%） than in adenocarcinomas （ADCs） （0-15.0%）. The rates of FGFRI amplification were as follows： males, 13.9-22.1%; females, 0-20.1%; Stage 1 NSCLC, 9.3-24.1%; Stage II NSCLC, 12.9-25.0%; Stage 111 NSCLC, 8.2-19.5%： Stage IV NSCLC, 0-12.5%; current smokers, 13.3-29.0%; former smokers, 2.5-23.0%; and nonsmokers, 0-22.2%. Overall survival was 43.9-70.8 months in patients with FGFRI amplification and 42.4-115.0 months in patients with no FGFRI amplification; disease-free survival was 22.5-58.5 months and 52.4-94.6 months, respectively. Conclusions： FGFR1 amplification is more frequent in SCCs than in ADCs. The association between FGFRI amplification and clinical characteristics （gender, smoking status, and disease stage） and the prognostic significance of FGFRI amplification in NSCLC remain controversial.
